Stem Cell Therapyespecially Umbilical Cord–derived Mesenchymal Stem Cells (UC-MSCs)has become one of the most discussed regenerative treatments in the world. From knee osteoarthritis to neurological recovery and longevity medicine, UC-MSCs are showing promising clinical outcomes across multiple medical fields.
So a very common question naturally arises: “If stem cells are that good, why don’t doctors recommend them as the first treatment?”
It’s a fair question. And the real answer has nothing to do with the treatment not working. Instead, it comes from a mix of medical guidelines, scientific caution, regulations, and the way healthcare systems adopt new therapies.

Medical Guidelines Change Slowly — Even When Research Moves Fast

Most global medical guidelines are conservative by design. They rely on large, long-term randomized controlled trials before updating official recommendations.

But regenerative medicine is a young, rapidly evolving field. UC-MSC studies have exploded only in the last 10–15 years, and many clinical trials—especially large-scale phase III trials—are still ongoing.

Examples of strong but still “early stage” data:

• Knee Osteoarthritis: UC-MSCs reduce pain, improve function, and show cartilage regeneration signals in MRI according to multiple RCTs
• Parkinson’s & Neurology: MSCs modulate neuroinflammation and protect dopaminergic neurons
• Stroke Recovery: Meta-analyses show functional improvement in motor and cognitive outcomes

While highly promising, guideline committees require decades of data, not a decade which means doctors aren’t avoiding stem cells but guidelines are just slow to catch up

Traditional Medicine Prioritizes “Standard of Care” First

Doctors must follow what is known as the standard of care the medically accepted, universally taught pathway for each condition. This protects both patients and doctors.

Even if stem cells show better or longer-lasting outcomes for some patients, they are still classified as adjunct or advanced therapies, not first-line options. Doctors simply cannot recommend a therapy before the officially approved steps unless the patient specifically seeks it out.

This is why most people who receive stem cell therapy are those who:

• tried standard treatments
• want to avoid surgery
• want biological repair, not symptom control
• want a less invasive, regenerative alternative

Many Doctors Lack Training in Regenerative Medicine

Regenerative medicine is not part of most medical school curricula. Most orthopedic, neurology, and internal medicine specialists were trained during an era when stem cell research wasn’t yet clinically applicable.

This means many doctors:

• don’t know the difference between embryonic vs adult MSCs
• are unfamiliar with UC-MSC potency
• assume all stem cells are the same
• aren’t aware of updated clinical trials
• confuse safe MSC therapy with older unethical embryonic practices

This is not their fault, medicine has expanded faster than training systems can update.

Some Doctors Still Believe Old Myths About Stem Cells

Common outdated beliefs include:

• “Stem cells are unproven.”

(False: over 1,400+ clinical trials are published worldwide.)

• “Stem cells can turn into cancer.”

(False: UC-MSCs are non-tumorigenic according to NIH and Frontiers, 2022.)

• “All stem cells are risky.”

(False: embryonic stem cells carry ethical/tumor risk, UC-MSCs do not.)

Insurance Systems Do Not Cover Regenerative Therapies Yet

This is a huge factor, as most insurance companies cover:

• medication
• injections
• surgery
• traditional rehabilitation

They rarely cover biological therapies like UC-MSCs. When a treatment is not reimbursed, doctors naturally use what insurance approves first. This doesn’t mean the treatment is ineffective. It only means healthcare policy hasn’t caught up yet just like how PRP was considered “experimental” until recently.

So… Do Doctors Recommend Stem Cells?

The number of doctors recommend Stem Cell treatment is increasing, but usually

• not as a first-line treatment
• not before conservative therapies fail
• not before understanding patient goals

Doctors who specialize in regenerative medicine (orthopedics, neurology, sports medicine, longevity) are already recommending MSCs regularly. Meanwhile, guideline updates, insurance policies, and clinician training simply need time to catch up. And the numbers are increasing as the 2024–2025 research continues to pile up, UC-MSC therapy is moving quickly toward mainstream acceptance

About EDNA Wellness

EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion

For more information or inquiries, contact us via

LINE @ednawellness

WhatsApp +66 (0) 64 505 5599

www.ednawellness.com

References

• Mayo Clinic Proceedings – MSC therapy overview and clinician knowledge gaps (2022)
• Frontiers in Bioengineering & Biotechnology – MSCs for knee OA MRI improvements (2021)
• NIH / National Library of Medicine – MSCs and neuroinflammation modulation (2023)
• Stem Cells Translational Medicine – MSCs for post-stroke recovery meta-analysis (2020)
• Nature Reviews Rheumatology – Mechanisms of MSC immunomodulation (2021)
• World Health Organization (WHO) – Cell therapy regulatory frameworks (2023)